Table 1.
Clinicopathological characteristics of 204 patients with diffuse large B-cell lymphoma (DLBCL) according to the expression of programmed cell death-ligand 1 (PD-L1) in tumor cells and tumor microenvironment
| Characteristic | PD-L1 expression in tumor cells [cases (%)] | P value | PD-L1 expression in tumor microenvironment [cases (%)] | P value | ||
|---|---|---|---|---|---|---|
| Negative | Positive | Negative | Positive | |||
| Total | 104 | 100 | 160 | 44 | ||
| Gender | 0.22 | 0.34 | ||||
| Male | 63 (60.6) | 52 (52.0) | 93 (58.1) | 22 (50.0) | ||
| Female | 41 (39.4) | 48 (48.0) | 67 (41.9) | 22 (50.0) | ||
| Age (years) | 0.78 | 0.92 | ||||
| ≤ 60 | 73 (70.2) | 72 (72.0) | 114 (71.2) | 31 (70.5) | ||
| > 60 | 31 (29.8) | 28 (28.0) | 46 (28.8) | 13 (29.5) | ||
| Clinical stage | 0.04 | 0.12 | ||||
| I–II | 58 (55.8) | 42 (42.0) | 83 (51.9) | 17 (38.6) | ||
| III–IV | 46 (44.2) | 58 (58.0) | 77 (48.1) | 27 (61.4) | ||
| B symptoms | 0.74 | 0.22 | ||||
| No | 75 (72.1) | 70 (70.0) | 117 (73.1) | 28 (63.6) | ||
| Yes | 29 (27.9) | 30 (30.0) | 43 (26.9) | 16 (36.4) | ||
| Spleen involvement | 0.19 | 0.22 | ||||
| No | 92 (88.5) | 82 (82.0) | 139 (86.9) | 35 (79.5) | ||
| Yes | 12 (11.5) | 18 (18.0) | 21 (13.1) | 9 (20.5) | ||
| IPI | 0.09 | 0.18 | ||||
| < 3 | 86 (82.7) | 73 (73.0) | 128 (80.0) | 31 (70.5) | ||
| ≥ 3 | 18 (17.3) | 27 (27.0) | 32 (20.0) | 13 (29.5) | ||
| Extranodal involvement | 0.67 | 0.88 | ||||
| No | 42 (40.4) | 44 (44.0) | 67 (41.9) | 19 (43.2) | ||
| Yes | 62 (59.6) | 56 (56.0) | 93 (58.1) | 25 (56.8) | ||
| Bulky diseasea | 0.91 | 0.82 | ||||
| No | 56 (70.0) | 63 (69.2) | 92 (69.2) | 27 (71.1) | ||
| Yes | 24 (30.0) | 28 (30.8) | 41 (30.8) | 11 (28.9) | ||
| LDHb (U/L) | 0.25 | 0.27 | ||||
| ≤ 245 | 55 (55.6) | 44 (47.3) | 81 (53.6) | 18 (43.9) | ||
| > 245 | 44 (44.4) | 49 (52.7) | 70 (46.4) | 23 (56.1) | ||
| ALPc (U/L) | 0.17 | 0.42 | ||||
| ≤ 110 | 93 (92.1) | 86 (86.0) | 138 (87.9) | 41 (93.2) | ||
| > 110 | 8 (7.9) | 14 (14.0) | 19 (12.1) | 3 (6.8) | ||
| β2-MGd (mg/L) | 0.06 | 0.01 | ||||
| ≤ 2.52 | 25 (69.4) | 21 (48.8) | 41 (66.1) | 5 (29.4) | ||
| > 2.52 | 11 (30.6) | 22 (51.2) | 21 (33.9) | 12 (70.6) | ||
| Ki-67e (%) | 0.74 | 0.75 | ||||
| < 90 | 45 (61.6) | 45 (64.3) | 70 (63.6) | 20 (60.6) | ||
| ≥ 90 | 28 (38.4) | 25 (35.7) | 40 (36.4) | 13 (39.4) | ||
| GCB subtypef | 0.02 | 0.04 | ||||
| Non-GCB | 61 (61.6) | 77 (77.0) | 102 (65.8) | 36 (81.8) | ||
| GCB | 38 (38.4) | 23 (23.0) | 53 (34.2) | 8 (18.2) | ||
| Rituximabg | 0.62 | 0.10 | ||||
| No | 40 (43.0) | 42 (46.7) | 59 (41.5) | 23 (56.1) | ||
| Yes | 53 (57.0) | 48 (53.3) | 83 (58.5) | 18 (43.9) | ||
| First-line chemotherapy CRh | 0.61 | 0.15 | ||||
| No | 31 (33.7) | 31 (36.9) | 46 (32.6) | 16 (45.7) | ||
| Yes | 61 (66.3) | 53 (63.1) | 95 (67.4) | 19 (54.3) | ||
| First-line chemotherapy resistancei | 0.36 | 0.03 | ||||
| No | 83 (90.2) | 72 (85.7) | 128 (90.8) | 27 (77.1) | ||
| Yes | 9 (9.8) | 12 (14.3) | 13 (9.2) | 8 (22.9) | ||
| Relapse | 0.12 | 0.93 | ||||
| No | 89 (85.6) | 77 (77.0) | 130 (81.2) | 36 (81.8) | ||
| Yes | 15 (14.4) | 23 (23.0) | 30 (18.8) | 8 (18.2) | ||
| Death | 0.09 | 0.34 | ||||
| No | 69 (66.3) | 55 (55.0) | 100 (62.5) | 24 (54.5) | ||
| Yes | 35 (33.7) | 45 (45.0) | 60 (37.5) | 20 (45.5) | ||
IPI international prognostic index, LDH lactate dehydrogenase, ALP anaplastic lymphoma kinase, β2-MG β2-microglobulin, GCB germinal center B-cell-like, CR complete remission
aThe data of 33 patients were missing
bThe data of 12 patients were missing
cThe data of 3 patients were missing
dThe data of 125 patients were missing
eThe data of 61 patients were missing
fThe data of 5 patients were missing
gThe data of 21 patients were missing
hThe data of 28 patients were missing
iThe data of 28 patients were missing